Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Descriptive study
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(G03F) PROGESTOGENS AND ESTROGENS IN COMBINATION
PROGESTOGENS AND ESTROGENS IN COMBINATION
Population studied

Short description of the study population

Women in all age groups with a prescription of a product containing an oestrogen alone or an oestrogen in combination with a progestogen between 1 st January 2000 and 31st December 2014.
For the UK, data were only available for a part of 2014, and hence, yearly prevalences are provided until 31 December 2013.

Age groups

  • Paediatric Population (< 18 years)
    • Neonate
      • Preterm newborn infants (0 – 27 days)
      • Term newborn infants (0 – 27 days)
    • Infants and toddlers (28 days – 23 months)
    • Children (2 to < 12 years)
    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Estimated number of subjects

200000
Study design details

Main study objective

Drug utilisation study of HRT

Data analysis plan

Prevalence and duration of exposure